NoNO Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5
Ending by 2030
Mar 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Therapy for Subarachnoid Hemorrhage and Ischemia (US 10,300,110) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Dec 23, 2026The maintenance fee for Treating stroke and other diseases without inhibiting N-type calcium channels (US 9,061,070) comes due Dec 23, 2026. Unpaid by Jun 23, 2027, it lapses early.
- 1 fee due Jan 7, 2027The maintenance fee for ND2 peptides and methods of treating neurological disease (US 9,073,976) comes due Jan 7, 2027. Unpaid by Jul 7, 2027, it lapses early.
- 1 fee due Apr 20, 2027The maintenance fee for Treatment for epilepsy (US 9,161,965) comes due Apr 20, 2027. Unpaid by Oct 20, 2027, it lapses early.
- 2 fees due Jul 23 to 26, 2027 · next Jul 23
- 1 fee due Aug 27, 2027The maintenance fee for Chloride salt of TAT-NR2B9C (US 11,911,438) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,061,070 | Treating stroke and other diseases without inhibiting N-type calcium channels In force · From the USPTO record | In force | From the USPTO record | |
| US 8,080,518 | Co-Administration of an Agent Linked to an Internalization Peptide with an Anti-Inflammatory In force · High confidence | In force | High confidence | |
| US 8,933,013 | Co-Administration of an Agent Linked to an Internalization Peptide with an Anti-Inflammatory In force · High confidence | In force | High confidence | |
| US 8,008,253 | Treatment for anxiety In force · From the USPTO record | In force | From the USPTO record | |
| US 8,940,699 | Model Systems and Treatment Regimes for Treatment of Neurological Disease In force · High confidence | In force | High confidence | |
| US 9,161,965 | Treatment for epilepsy In force · From the USPTO record | In force | From the USPTO record | |
| US 9,073,976 | ND2 peptides and methods of treating neurological disease In force · From the USPTO record | In force | From the USPTO record | |
| US 11,878,044 | Combination Therapy for Ischemia In force · High confidence | In force | High confidence | |
| US 9,241,970 | Therapy for Subarachnoid Hemorrhage and Ischemia In force · Medium confidence | In force | Medium confidence | |
| US 10,300,110 | Therapy for Subarachnoid Hemorrhage and Ischemia In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 17: 17 lapsed for an unpaid fee · 6 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 5 abandoned · 8 no status recorded